Human CD109 antigen(CD109) ELISA kit

Code CSB-EL004878HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
CD109 molecule
Alternative Names
150 KDa TGF beta 1 binding protein ELISA Kit; 150 KDa TGF-beta-1-binding protein ELISA Kit; 7D1 ELISA Kit; 8A3 ELISA Kit; Activated T cell marker CD109 ELISA Kit; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7 ELISA Kit; CD 109 ELISA Kit; CD109 ELISA Kit; CD109 antigen ELISA Kit; CD109_HUMAN ELISA Kit; CPAMD7 ELISA Kit; DKFZp762L1111 ELISA Kit; E123 ELISA Kit; FLJ38569 ELISA Kit; FLJ41966 ELISA Kit; Gov system alloantigens on platelets ELISA Kit; p180 ELISA Kit; Platelet specific Gov antigen ELISA Kit; Platelet-specific Gov antigen ELISA Kit; r150 ELISA Kit; RP11 525G3.1 ELISA Kit
Abbreviation
CD109
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
94 pg/mL-6000 pg/mL
Sensitivity
23.4 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CD109 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %89
Range %85-92
1:2Average %84
Range %80-88
1:4Average %96
Range %93-99
1:8Average %102
Range %98-106
Recovery
The recovery of human CD109 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9490-98
EDTA plasma (n=4)8581-89
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
60002.008 2.157 2.083 1.928
30001.604 1.630 1.617 1.462
15001.191 1.175 1.183 1.028
7500.784 0.772 0.778 0.623
3750.472 0.498 0.485 0.330
187.50.304 0.315 0.310 0.155
940.212 0.216 0.214 0.059
00.152 0.157 0.155
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human CD109 ELISA Kit was designed for the quantitative measurement of Human CD109 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 94 pg/mL-6000 pg/mL and the sensitivity is 23.4 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Modulates negatively TGFB1 signaling in keratinocytes.
Gene References into Functions
  1. GRP78 binds to and acts in concert with a glycosylphosphatidylinositol-anchored protein, CD109, in blocking TGF-beta signaling by promoting the routing of the TGF-beta receptor to the caveolae, thereby disrupting its binding to and activation of Smad2. PMID: 29654145
  2. CD109 knockdown upregulated IL-8 expression through activation of TGF-beta/Akt/NF-kappaB pathway in human umbilical vein endothelial cells PMID: 27121053
  3. High expression of CD109 in brain tumor stem cells is involved in glioma progression. PMID: 28888050
  4. The CD109 protein was up-regulated in hepatocellular carcinoma tissue compared with adjacent noncancerous tissue. CD109 shRNA knockdown delayed the G1-S phase transition, abrogated cell proliferation, and increased cell apoptosis. Furthermore, CD109 impaired TGF-beta/Smad signaling through control of p-smad2. PMID: 27074923
  5. CD109 is a putative biomarker for identifying a high-risk group among DLBCL patients. PMID: 28032275
  6. Expression levels of CD109 was reduced significantly in psoriasis. Lower expression of CD109 and TGF-beta RI was highly correlated with higher expression of Smad7 and Ki67, suggesting that CD109 may induce the pathogenesis of psoriasis through Smad7-mediated degradation of TGF-beta RI. PMID: 26838754
  7. sCD109 can bind TGF-beta, inhibit TGF-beta binding to its receptors and decrease TGF-beta signalling and TGF-beta-induced cellular responses. PMID: 26621871
  8. These findings indicate that CD109 is an exosomal protein and that the C-terminal region of CD109 is required for its presence in the exosome. PMID: 26707640
  9. CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas. PMID: 26249215
  10. CD109 is specifically expressed in endothelial cells of cutaneous cavernous haemangioma. PMID: 25388101
  11. expression increased in cutaneous squamous cell carcinoma PMID: 25271095
  12. The results suggest that circulating endothelial cells express CD109 and represent a rare population of circulating tumor endothelial cells, that play a potentially useful prognostic role in patients with glioblastoma. PMID: 25506915
  13. CD109 overexpression was significantly associated with surgical stage, distant metastasis, and poor prognosis in myxofibrosarcoma. PMID: 26031650
  14. Three glioblastoma cell lines, SK-MG-1, U251MG and MG178, were tested and CD109 overexpression attenuated TGF-beta1 signaling and enhanced EGF signaling in SK-MG-1, but not in U251MG or MG178. PMID: 25724945
  15. CD109 is highly expressed in TNBC and is a potential biomarker for the initiation, progression, and differentiation of breast cancer tumors. PMID: 25149155
  16. CD109 plays a critical role in non-small-cell lung cancer (NSCLC) progression, and is overexpressed in advanced NSCLC PMID: 24667143
  17. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in a novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PMID: 24376795
  18. Hematopoietic cell marker CD109 is expressed in hepatic progenitor cells. PMID: 24396288
  19. expression of CD109 (human platelet antigen 15) mRNA is different in various human cell types PMID: 23509816
  20. The upregulation of CD109 protein in SSc may represent an adaptation or consequence of aberrant TGF-beta signaling in systemic sclerosis PMID: 22694813
  21. CD109 is an important regulator of SMAD7/Smurf2-mediated degradation of TGFBR1. PMID: 21898545
  22. CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation. PMID: 21539622
  23. CD109 regulates TGF-beta receptor endocytosis and degradation to inhibit TGF-beta signaling. PMID: 21295082
  24. Report PRSS3/mesotrypsin upregulation in breast cancer cells and identify CD109 as the functional proteolytic target of mesotrypsin. PMID: 20035377
  25. These findings suggest that CD109 is involved in bladder tumorigenesis and is a potential target for cancer immunotherapy. PMID: 20946523
  26. Processing of CD109 into 180 kDa and 25 kDa proteins by furin, followed by complex formation with the type I TGF-beta receptor is required for the regulation of TGF-beta signaling in cancer cells and keratinocytes. PMID: 20101215
  27. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. cDNA sequence determination and protein structure analysis given. PMID: 11861284
  28. A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens. PMID: 11861285
  29. Findings suggest that CD109 may become a molecular target for the development of new therapeutics for squamous cell carcinoma of various tissue origins. PMID: 15826242
  30. CD109 plays a unique role in the regulation of isoform-specific TGF-beta signaling in keratinocytes. PMID: 16754747
  31. Findings indicate that CD109 is a useful marker for the diagnosis of invasive breast and prostate carcinomas. PMID: 17493171
  32. the novel gene HEPT3 may function through its noncoding RNA and its overexpression may play a role in hepatocarcinogenesis [HEPT3] PMID: 17611685
  33. CD109 expression may play a role in the development of lung squamous cell carcinoma. PMID: 17922683
  34. Up-regulation of CD109 expression is associated with carcinogensis of the squamous epithelium of the oral cavity. PMID: 19016750
  35. Found with a mutation in 7% of colon cancers studied. PMID: 16959974

Show More

Hide All

Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor.
Protein Families
Protease inhibitor I39 (alpha-2-macroglobulin) family
Tissue Specificity
Widely expressed with high level in uterus, aorta, heart, lung, trachea, placenta and in fetal heart, kidney, liver, spleen and lung. Expressed by CD34(+) acute myeloid leukemia cell lines, T-cell lines, activated T-lymphoblasts, endothelial cells and act
Database Links

HGNC: 21685

OMIM: 608859

KEGG: hsa:135228

STRING: 9606.ENSP00000287097

UniGene: Hs.399891

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X